Safety and tolerability of allogeneic dendritic cell vaccination with induction of Wilms tumor 1-specific T cells in a pediatric donor and pediatric patient with relapsed leukemia: a case report and review of the literature.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 25484308.
- Also identified by DOI 10.1016/j.jcyt.2014.10.003.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A 15-year-old girl with acute lymphoblastic leukemia received allogeneic dendritic cell vaccination, pulsed with Wilms tumor 1 (WT1) peptide, after her third hematopoietic stem cell transplantation (HSCT). The vaccines were generated from the third HSCT donor, who was her younger sister, age 12 years. The patient received 14 vaccines and had no graft-versus-host disease or systemic adverse effect, aside from grade 2 skin reaction at the injection site. WT1-specific immune responses were detected after vaccination by both WT1-tetramer analysis and enzyme-linked immunosorbent spot assay. This strategy may be safe, tolerable and even feasible for patients with a relapse after HSCT.
Medical subject headings
- Cancer Vaccines
- Dendritic Cells
- Hematopoietic Stem Cell Transplantation
- Peptide Fragments
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- T-Lymphocytes
- WT1 Proteins